Company Description

Vincere Biosciences is developing mitochondrial-targeted therapies for Parkinson’s disease and acute kidney injury. Its novel class of non-covalent small molecules inhibits USP30, a key regulator of mitophagy, to enhance mitochondrial quality control. Identified using a proprietary computer-based method, these molecules aim to restore cellular health in diseases driven by mitochondrial dysfunction.